Cargando…

Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity

Detalles Bibliográficos
Autores principales:	Redmond, William L, Linch, Stefanie N, Kasiewicz, Melissa J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991178/ http://dx.doi.org/10.1186/2051-1426-1-S1-P87

Ejemplares similares

Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
por: Linch, Stefanie N, et al.
Publicado: (2013)

Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
por: Linch, Stefanie, et al.
Publicado: (2015)

Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts
por: Linch, Stefanie N, et al.
Publicado: (2014)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity
por: Sturgill, Elizabeth R., et al.
Publicado: (2021)

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
por: Linch, Stefanie N., et al.
Publicado: (2015)

The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities
por: Bjorck, Pia, et al.
Publicado: (2015)

T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis
por: Zheng, Chunjiao, et al.
Publicado: (2023)

Aberrant Expressions of Co-stimulatory and Co-inhibitory Molecules in Autoimmune Diseases
por: He, Weiwei, et al.
Publicado: (2019)

CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells
por: Guercio, Marika, et al.
Publicado: (2020)

The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease
por: Kumar, Sandeep, et al.
Publicado: (2018)

Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations
por: Reckamp, Karen L, et al.
Publicado: (2020)

Hypothesis Testing: CTLA4 Co-stimulatory Pathways Critical in the Pathogenesis of Human and Mouse Alopecia Areata
por: Sundberg, John P., et al.
Publicado: (2011)

Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study
por: Basso, Daniela, et al.
Publicado: (2013)

The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis
por: Ruderman, Eric M, et al.
Publicado: (2005)

Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
por: Ville, Simon, et al.
Publicado: (2015)

OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer
por: Montler, Ryan, et al.
Publicado: (2016)

Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis
por: Chang, Katherine C, et al.
Publicado: (2013)

OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021)

Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression
por: Redmond, William L., et al.
Publicado: (2012)

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
por: Wei, Huafeng, et al.
Publicado: (2014)

What do we know about co-stimulatory and co-inhibitory immune checkpoint signals in ankylosing spondylitis?
por: Schütz, Christian, et al.
Publicado: (2023)

SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
por: Hederman, Andrew P., et al.
Publicado: (2023)

Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
por: Zhang, Di, et al.
Publicado: (2016)

S80. Prolongation of T cell response by OX40 co-signalling CARS
por: Abken, H
Publicado: (2014)

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012)

OX40/OX40L axis: not a friend in autoimmunity
por: Ueno, Hideki, et al.
Publicado: (2015)

Galectin-3 inhibition using novel inhibitor GR-MD-02 improves survival and immune function while reducing tumor vasculature
por: Linch, Stefanie, et al.
Publicado: (2015)

Inhibitory action of a macrolide antibiotic, roxithromycin, on co-stimulatory molecule expressions in vitro and in vivo.
por: Suzuki, Mayumi, et al.
Publicado: (2002)

Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression
por: Yu, Guangjie, et al.
Publicado: (2016)

T-cell co-stimulatory pathways in autoimmunity
por: Goronzy, Jörg J, et al.
Publicado: (2008)

SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations
por: Hederman, Andrew P., et al.
Publicado: (2022)

Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells
por: McNamara, Michael J, et al.
Publicado: (2014)

Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome
por: Kawana, Yuki, et al.
Publicado: (2021)

Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy
por: Chester, Cariad, et al.
Publicado: (2015)

Airway Wall Expression of OX40/OX40L and Interleukin-4 in Asthma
por: Siddiqui, Salman, et al.
Publicado: (2010)

Expression of gp34 (OX40 Ligand) and OX40 on Human T Cell Clones
por: Takasawa, Naruhiko, et al.
Publicado: (2001)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
por: Cui, Dawei, et al.
Publicado: (2019)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

INHIBITORY AND STIMULATORY EFFECTS OF CONCANAVALIN A ON THE RESPONSE OF MOUSE SPLEEN CELL SUSPENSIONS TO ANTIGEN : II. EVIDENCE FOR SEPARATE STIMULATORY AND INHIBITORY CELLS
por: Dutton, Richard W.
Publicado: (1973)

Cannot write session to /tmp/vufind_sessions/sess_7f9hkbpo9q6tde1j4uu8ug3mue